glp-1 weight loss bellevue Injections Semaglutide Weight Loss Program Bellevue

Journal of Diabetes Science and Technology

Phase 3 TRIUMPH trials are ongoing, with early TRIUMPH-4 data showing 28.7% weight loss at 68 weeks

Comorbidities: Type 2 diabetes: Both are FDA-approved for diabetes (tirzepatide as Mounjaro, semaglutide as Ozempic) Cardiovascular disease: Semaglutide has the cardiovascular outcomes data Sleep apnea: Tirzepatide has shown benefits Injection frequency: Both are once-weekly

If you are following a standard tirzepatide dose escalation schedule or semaglutide dosing chart , expect potential sulfur burp recurrence at each step up

At Capital Health , were committed to helping our patients achieve their healthcare and weight loss goals

doi: 10.3390/nu15224809